Phase 2a Study of HU6, Rivus Pharmaceuticals’ Investigational Controlled Metabolic Accelerator, Demonstrates Clinical Benefit in Patients with High Body Mass Index and Nonalcoholic Fatty Liver Disease

– Results showing significant reductions in liver fat content and body weight, no loss of lean muscle mass, and improvement in key markers of metabolism and inflammation published in The Lancet Gastroenterology & Hepatology –

– HU6 was well tolerated at once-daily oral doses with adverse events mainly mild or moderate in severity

Excerpt from the Press Release:

CHARLOTTESVILLE, Va. and SAN FRANCISCO, Oct. 5, 2023 /PRNewswire/ — Rivus Pharmaceuticals Inc., a clinical-stage biopharmaceutical company dedicated to improving cardiometabolic health, today announced publication in The Lancet Gastroenterology & Hepatology of the results of a Phase 2a metabolic study of HU6, an investigational first-in-class controlled metabolic accelerator (CMA), in patients with nonalcoholic fatty liver disease (NAFLD), also known as metabolic dysfunction-associated steatotic liver disease (MASLD), and a high body mass index (BMI).

Results showed that HU6 significantly reduced liver fat compared with placebo in both the overall study population and in study participants at increased risk of Type 2 diabetes. HU6 also reduced body weight, with no loss of lean muscle mass, and improved measures of metabolism and systemic inflammation. HU6, the company’s lead medicine, is an oral, controlled metabolic accelerator in Phase 2 clinical development.

“The positive efficacy and safety results of this Phase 2a metabolic clinical trial of HU6 give us confidence that this first-in-class therapy has the potential to provide an effective, well-tolerated treatment for a broad range of cardiometabolic diseases associated with obesity,” said Mazen Noureddin, M.D., hepatologist at Houston Research Institute and Houston Methodist Hospital and lead author of the publication. “A broad range of investigational therapies have been studied in patients with NAFLD/MASLD, but there are still not many options that are able to effectively manage this disease in patients with obesity and elevated liver fat. The significant reductions in liver fat, coupled with greater than expected reductions in inflammatory markers, make HU6 a promising new approach.”

Click the button below to read the entire Press Release:

Continue Reading The Press Release